Affiliated with the American Association for Cellular and Computational Toxicology and the European Society for Toxicology in Vitro.

Toxicology in Vitro publishes original research papers, reviews and workshop reports focusing on the application and use of in vitro and in silico systems for toxicological evaluations (collectively described as New Approach Methodologies (NAM)). This includes the utilisation or the development of NAMs for assessing the potential adverse effects of chemicals for human safety assessment. In vitro techniques include primary cells, tissue slices, cell lines and stem cells (adult, embryonic and induced Pluripotent cells) or subcellular preparations thereof. Our journal strongly supports the Reduction, Refinement and Replacement (3R) of animals in toxicology evaluations.

This is a wide topic and thus we have certain preferences including:
Development of in vitro techniques and their application to research and regulatory use (i.e. 3R principle.
Mechanistic underpinning of data.
Ability to translate outcome to human safety assessment.
We strongly encourage :
The use of normal (non-transformed) human cells (where appropriate).
Reporting the Short Tandem Repeat (STR) profile of the cells used (especially when cells have been provided as a gift or generated in house).
Free access to raw (or primary) data.
Appropriate model characterisation.
The use (or reduction) of animal free components, including serum. [Especially when the system was already developed under such conditions, such as the HK-2 cell line].
Attention to detailed methodology and appropriate statistics. [Readers need to know how you did the experiment, how many times, how many replicates etc?]
Reporting the source of the compounded tested, catalogue no. and lot no. Where the chemical has been purified or synthesised a full analytical report is expected.
Quantification of compounds in exposure medium and/or cells over time (biokinetics).


We do not accept solely in vivo investigations and rarely accept animal in vivo, in vitro hybrid papers, except where the animal data was critical in the interpretation or validation of the in vitro data (and not merely confirmatory).

We generally discourage investigations relating:
Unidentified mixtures - for example in plant extracts.
Solely pharmacological investigations (e.g. demonstrating your chemical kills cancer cells in vitro is not generally acceptable).
Use of non-human cells when human equivalents exist and are available.
The lack of adherence to established protocols, without direct explanation.
Reporting cytotoxicity alone, with no mechanistic underpinning and/or no estimation of chemical exposure.

original research papers
reviews
Brief Communications

Editors-in-Chief
Bas J. Blaauboer
Inst. for Risk Assessment Sciences (IRAS), Universiteit Utrecht, P.O. Box 80177, 3508 TD, Utrecht, Netherlands Email Bas J. Blaauboer
Paul Jennings
Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, De Boelelaan, 1108, 1081 HZ Amsterdam, The NetherlandsEmail Paul Jennings
Associate Editors
Kerstin Stemmer
Institute for Diabetes and Obesity (IDO), Division of Metabolism and Cancer, Helmholtz Centre Munich, Business Campus Garching, Parkring 13, 85748 Garching, GermanyEmail Kerstin Stemmer
Mathieu Vinken
Teacher Education Department, Vrije Universiteit Brussel (VUB), Brussels, Belgium Email Mathieu Vinken
Julio Davila
Dept. of Biochemistry, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico Email Julio Davila
Matteo Goldoni
Dept. of Medicine and Surgery and Centre of Toxicological Research (CERT), Università degli Studi di Parma, Via Gramsci 14, 43126, Parma, Italy Email Matteo Goldoni
Maxime Culot
BBB Laboratory - Laboratoire de la Barrière hémato-encéphalique, Université d'Artois, LBHE - EA2465, France Email Maxime Culot
Martin Leonard
Centre for Radiation, Chemical and Environmental Hazards, Toxicology Department, Public Health England, Harwell Science and Innovation Campus, OX11 0RQ, Oxfordshire, England, UK Email Martin Leonard
International Editorial Board
Daniel Acosta
James Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA
Armelle Baeza-Squiban
Inst. de Mathematiques de Jussieu, Université Paris Diderot (Paris 7), Paris, France
Gáspár Bánfalvi
Dept. of Microbial Biotechnology and Cell Biology, University of Debrecen, Debrecen, Hungary
Frank A. Barile
Dept. of Pharmaceutical Sciences, St. John's University, Queens, New York, USA
Martin D. Barratt
Marlin Consultancy, Bedford, England, UK
Robert L. Bronaugh
Office of Cosmetics and Colors, HFS-125, CPK2, Food and Drug Administration (FDA), College Park, Maryland, USA
Robert D. Combes
FRAME, 96-98 North Sherwood Street, Nottingham, NG1 4EE, UK
Gianni Dal Negro
Comparative Biology and Medicine, GlaxoSmithKline, Verona, Italy
George L. DeGeorge
Toxicology, MB Research Labs, Spinnerstown, Pennsylvania, USA
Marion Ehrich, PhD, DABT
Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute & State University, Blacksburg, Virginia, USA
Mary Beth Genter
College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA
Mary Helen Grant
Bioengineering Unit, University of Strathclyde, Glasgow, Scotland, UK
Roberta L. Grant
Toxicology Section, Texas Commission on Environmental Quality, Austin, Texas, USA
Stephen G. Grant
Dept. of Environmental and Occupational Health, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA
Alison Gray
In Vitro Toxicology, Thor Personal Care SAS, Compiègne Cedex, France
Sjeng Horbach
Dept. of Toxicology and Drug Disposition, N.V. Organon, Oss, Netherlands
Ian Kimber
Fac. of Life Sciences, University of Manchester, Manchester, England, UK
Angela Mally
Dept. of Toxicology (Institut für Toxikologie), Julius-Maximilians-Universität Würzburg, Würzburg, Germany
José E. Manautou, PhD
Dept. of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, USA
Marina Marinovich
Dip. di Scienze Farmacologiche (Pharmacological Science), Università degli Studi di Milano, Milano, Italy
Russell Melchert
College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Nancy Monteiro-Riviere
Ctr. for Chemical Toxicology Research and Pharmacokinetics (CCTRP), North Carolina State University, Raleigh, North Carolina, USA
Daniel Morgan
Respiratory Toxicology, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina, USA
Marek Murias
Dept. of Toxicology, Poznań University of Medical Sciences, Poznan, Poland
Minako Nagao
Div. of Biochemistry, National Cancer Center Research Institute, Tokyo, Japan
Andreas Natsch
Bioscience, Givaudan Scweiz AG, Dübendorf, Switzerland
Andreas K. Nüssler
Dept. of Traumatology - Abteilung für Unfallchirurgie, Technische Universität München, München, Germany
L. Garza Ocañas
Dept. of Pharmacology & Toxicology, Universidad Autónoma de Nuevo León, Garza Garcia, Nuevo León, Mexico
José-Enrique O'Connor
Centro de Citometría y Citómica, Universitat de València, Valencia, Spain
Alvaro Puga
Ctr. for Environmental Genetics, University of Cincinnati, Cincinnati, Ohio, USA
Ivonne M.C.M. Rietjens
Sectie Toxicologie, Wageningen Universiteit, Wageningen, Netherlands
Rosita Rodriguez Proteau
Pharmaceutics & Toxicology, Oregon State University, Corvalis, Oregon, USA
Hasso Seibert
Inst. fur Toxikologie und Pharmakologe fur Naturwissenschaftler, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Andrzej C. Skladanowski
Dept. of Molecular Enzymology, Medical University of Gdańsk, Gdansk, Poland
Miguel Sogorb
Instituto de Bioingeniería, Universidad Miguel Hernández de Elche (UMH), Elche, Spain
Emanuela Testai
Lab. TCE, Istituto Superiore di Sanità, Roma, Italy
Chiara Urani
Dept. of Earth and Environmental Sciences, Università degli Studi di Milano-Bicocca, Milano, Italy
Jan van Benthem
Dept. of Carcinogenesis, Mutagenesis and Reproduction Toxicology, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, Netherlands
Bart van der Burg
BioDetection Systems BV (BDS), Amsterdam, Netherlands
Remco Westerink, PhD
Inst. for Risk Assessment Sciences (IRAS), Universiteit Utrecht, Utrecht, Netherlands
Xiaozhong (John) Yu
College of Public Health, University of Georgia, Athens, Georgia, USA